Intercept Pharmaceuticals (NASDAQ:ICPT) was upgraded by investment analysts at Oppenheimer from a “market perform” rating to an “outperform” rating in a research note issued to investors on Monday, MarketBeat reports. The brokerage currently has a $140.00 price objective on the biopharmaceutical company’s stock. Oppenheimer’s target price would indicate a potential upside of 31.15% from the company’s current price. Oppenheimer also issued estimates for Intercept Pharmaceuticals’ Q1 2019 earnings at ($2.11) EPS, Q2 2019 earnings at ($1.66) EPS, Q3 2019 earnings at ($1.48) EPS and Q4 2019 earnings at ($1.64) EPS.

A number of other equities research analysts have also recently weighed in on the company. UBS Group upgraded Intercept Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Monday. Zacks Investment Research cut Intercept Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, November 16th. ValuEngine cut Intercept Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, November 12th. Wedbush set a $220.00 price objective on Intercept Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, November 6th. Finally, Needham & Company LLC restated a “hold” rating on shares of Intercept Pharmaceuticals in a research note on Wednesday, October 31st. Eight investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. Intercept Pharmaceuticals has an average rating of “Buy” and a consensus price target of $143.06.

Shares of NASDAQ ICPT opened at $106.75 on Monday. The company has a debt-to-equity ratio of 3.83, a current ratio of 5.98 and a quick ratio of 5.98. The firm has a market cap of $3.05 billion, a P/E ratio of -7.42 and a beta of -1.08. Intercept Pharmaceuticals has a 1-year low of $51.05 and a 1-year high of $133.74.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Wednesday, October 31st. The biopharmaceutical company reported ($2.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.65) by $0.47. The firm had revenue of $47.00 million during the quarter, compared to analysts’ expectations of $48.24 million. Intercept Pharmaceuticals had a negative return on equity of 645.54% and a negative net margin of 202.93%. The firm’s quarterly revenue was up 13.8% on a year-over-year basis. During the same period in the prior year, the business posted ($2.89) EPS. As a group, equities analysts forecast that Intercept Pharmaceuticals will post -10 EPS for the current fiscal year.

In other Intercept Pharmaceuticals news, insider David Shapiro sold 4,917 shares of the stock in a transaction dated Wednesday, September 5th. The stock was sold at an average price of $111.43, for a total value of $547,901.31. Following the completion of the sale, the insider now directly owns 42,196 shares in the company, valued at $4,701,900.28. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Mark Pruzanski sold 50,000 shares of the stock in a transaction dated Friday, November 16th. The shares were sold at an average price of $101.07, for a total value of $5,053,500.00. Following the completion of the sale, the chief executive officer now owns 589,199 shares of the company’s stock, valued at $59,550,342.93. The disclosure for this sale can be found here. Over the last quarter, insiders sold 61,101 shares of company stock valued at $6,230,628. 4.90% of the stock is currently owned by company insiders.

A number of institutional investors have recently added to or reduced their stakes in ICPT. State of Wisconsin Investment Board increased its holdings in shares of Intercept Pharmaceuticals by 95.9% in the second quarter. State of Wisconsin Investment Board now owns 22,700 shares of the biopharmaceutical company’s stock valued at $1,905,000 after purchasing an additional 11,111 shares during the period. FMR LLC increased its holdings in shares of Intercept Pharmaceuticals by 17.5% in the second quarter. FMR LLC now owns 4,437,332 shares of the biopharmaceutical company’s stock valued at $372,336,000 after purchasing an additional 661,542 shares during the period. Schwab Charles Investment Management Inc. increased its holdings in shares of Intercept Pharmaceuticals by 104.3% in the second quarter. Schwab Charles Investment Management Inc. now owns 110,805 shares of the biopharmaceutical company’s stock valued at $9,298,000 after purchasing an additional 56,556 shares during the period. Asymmetry Capital Management L.P. acquired a new position in shares of Intercept Pharmaceuticals in the second quarter valued at about $2,175,000. Finally, Rhumbline Advisers increased its holdings in shares of Intercept Pharmaceuticals by 11.5% in the second quarter. Rhumbline Advisers now owns 21,153 shares of the biopharmaceutical company’s stock valued at $1,775,000 after purchasing an additional 2,181 shares during the period. Institutional investors own 63.20% of the company’s stock.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR).

Featured Story: What does cost of debt say about a company’s financial health?

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.